GenScript Biotech, a global biotechnology company, has announced that its CDMO subsidiary, ProBio, has licensed its proprietary PD-1 new molecular entity (NME) to LaNova Medicines. This licensing agreement has paved the way for LaNova’s PD-1/VEGF bispecific antibody program, LM-299, which
GenScript Biotech Corporation has announced the opening of a new operations site and logistics center in Sydney, Australia. This expansion aims to streamline the delivery of biotechnology research materials across the region, marking GenScript’s increased commitment to the Asia-Pacific market.
GenScript Biotech Corporation has been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally respected rating agency. MSCI evaluates thousands of companies globally, assessing their ESG performance and risk management. The agency’s
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
